![PDF) Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting PDF) Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting](https://i1.rgstatic.net/publication/362486907_Morbidity_and_mortality_of_sickle_cell_disease_patients_is_unaffected_by_splenectomy_evidence_from_3_decades_follow-up_in_a_high-income_setting/links/636a4b5f37878b3e87911fae/largepreview.png)
PDF) Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting
![Cells | Free Full-Text | Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia Cells | Free Full-Text | Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia](https://www.mdpi.com/cells/cells-10-00734/article_deploy/html/images/cells-10-00734-g001.png)
Cells | Free Full-Text | Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin | Haematologica
Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis | Haematologica
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin | Haematologica
![Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease](https://article.imrpress.com/journal/FBE/14/3/10.31083/j.fbe1403018/1945-0508-14-3-018/fig1.jpg)
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease
![Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - The Lancet Haematology Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - The Lancet Haematology](https://www.thelancet.com/cms/attachment/8ea69c89-10c4-44c8-81ad-abcf8b3d7df2/gr1_lrg.jpg)
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - The Lancet Haematology
![Cancers | Free Full-Text | Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia? Cancers | Free Full-Text | Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?](https://pub.mdpi-res.com/cancers/cancers-14-05655/article_deploy/html/images/cancers-14-05655-ag.png?1669187241)
Cancers | Free Full-Text | Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?
![Generation of an immortalised erythroid cell line from haematopoietic stem cells of a haemoglobin E/β-thalassemia patient | Scientific Reports Generation of an immortalised erythroid cell line from haematopoietic stem cells of a haemoglobin E/β-thalassemia patient | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-020-73991-4/MediaObjects/41598_2020_73991_Fig1_HTML.png)
Generation of an immortalised erythroid cell line from haematopoietic stem cells of a haemoglobin E/β-thalassemia patient | Scientific Reports
![Efficient manufacturing and engraftment of CCR5 gene-edited HSPCs following busulfan conditioning in nonhuman primates: Molecular Therapy - Methods & Clinical Development Efficient manufacturing and engraftment of CCR5 gene-edited HSPCs following busulfan conditioning in nonhuman primates: Molecular Therapy - Methods & Clinical Development](https://www.cell.com/cms/attachment/b830f429-fd92-4dcf-974c-a5b8d42b393f/gr3.jpg)